張文娟,方開(kāi)云
(1.貴州醫(yī)科大學(xué), 貴州 貴陽(yáng) 550025; 2.貴州醫(yī)科大學(xué)附屬省人民醫(yī)院 麻醉科, 貴州 貴陽(yáng) 550001)
?
不同劑量右美托咪定對(duì)神經(jīng)外科手術(shù)患者全身麻醉恢復(fù)質(zhì)量的影響
張文娟1*,方開(kāi)云2**
(1.貴州醫(yī)科大學(xué), 貴州 貴陽(yáng)550025; 2.貴州醫(yī)科大學(xué)附屬省人民醫(yī)院 麻醉科, 貴州 貴陽(yáng)550001)
[摘要]目的: 研究不同劑量右美托咪定(Dex)對(duì)神經(jīng)外科手術(shù)病人全身麻醉恢復(fù)質(zhì)量的影響。方法: 接受神經(jīng)外科手術(shù)患者120例,根據(jù)術(shù)中Dex用量隨機(jī)分為低、中和高劑量組,比較3組患者蘇醒過(guò)程中的躁動(dòng)評(píng)分以及鎮(zhèn)靜評(píng)分、呼吸恢復(fù)時(shí)間、呼之睜眼時(shí)間、拔管時(shí)間、心率(HR)、心臟指數(shù)(CI)、心率與收縮壓乘積(RPP);檢查蘇醒過(guò)程中應(yīng)激反應(yīng)指標(biāo)包括皮質(zhì)醇(Cor)、腎上腺素(E)及去甲腎上腺素(NE)。結(jié)果: 大劑量組和中劑量組患者的躁動(dòng)評(píng)分低于低劑量組、鎮(zhèn)靜評(píng)分高于低劑量組(P<0.05),但兩組間躁動(dòng)評(píng)分、鎮(zhèn)靜評(píng)分差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);低劑量組和中劑量組的呼吸恢復(fù)時(shí)間、呼之睜眼時(shí)間、拔管時(shí)間短于高劑量組(P<0.05),且兩組間的蘇醒時(shí)間差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);大劑量組和中劑量組患者的HR、CI、RPP、Cor、NE、E均低于低劑量組(P<0.05),且中劑量和大劑量間的生命體征和應(yīng)激激素含量差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。結(jié)論: 中劑量Dex的蘇醒效果最理想,能夠減輕躁動(dòng)程度、穩(wěn)定生命體征、緩解應(yīng)激反應(yīng),同時(shí)不延長(zhǎng)蘇醒時(shí)間。
[關(guān)鍵詞]右美托咪定; 神經(jīng)外科手術(shù); 麻醉,全身; 鎮(zhèn)靜; 應(yīng)激
右美托咪定(Dex)是一類(lèi)新型麻醉藥物,屬于α2腎上腺素受體激動(dòng)劑,能夠激活藍(lán)斑核突觸前膜的α2腎上腺素受體、減少去甲腎上腺素釋放,進(jìn)而降低突觸結(jié)構(gòu)的興奮性[1]。由藍(lán)斑核發(fā)出的腎上腺素能神經(jīng)纖維具有調(diào)控大腦皮層覺(jué)醒反應(yīng)的功能,在全身麻醉的同時(shí)應(yīng)用右美托咪定,能夠發(fā)揮該藥物對(duì)藍(lán)斑核腎上腺素能神經(jīng)的調(diào)節(jié)作用,抑制大腦的覺(jué)醒反應(yīng),進(jìn)而保證確切的麻醉效果及麻醉蘇醒期平穩(wěn)進(jìn)行,同時(shí)也減少蘇醒期發(fā)生躁動(dòng)的風(fēng)險(xiǎn)[2-3]。目前關(guān)于Dex的劑量選擇尚無(wú)統(tǒng)一認(rèn)識(shí)。本文采取隨機(jī)對(duì)照研究,比較不同劑量Dex對(duì)神經(jīng)外科手術(shù)病人全身麻醉恢復(fù)質(zhì)量的影響。
1資料與方法
1.1一般資料
選擇2014年11月~2015年9月接受神經(jīng)外科手術(shù)的患者120例,其中顱內(nèi)腫瘤切除術(shù)67例,顱骨缺損修補(bǔ)術(shù)32例,顱內(nèi)動(dòng)脈瘤夾閉術(shù)21例,所有患者均符合疾病診斷和手術(shù)指征,報(bào)請(qǐng)醫(yī)院倫理委員會(huì)批準(zhǔn),告知研究事項(xiàng),且所有患者均簽署知情同意書(shū)。排除嚴(yán)重心、肝、腎等器官疾病患者、精神與神經(jīng)疾病患者、長(zhǎng)期大劑量服用鎮(zhèn)靜藥物患者,用體質(zhì)過(guò)敏患者。男65例,女55例; 18~60歲,平均(35.24±4.32)歲;體重44~78 kg,平均(53.14±5.42)kg。根據(jù)美國(guó)麻醉師協(xié)會(huì)病情分級(jí):Ⅱ級(jí)70例,Ⅲ級(jí)50例。根據(jù)術(shù)中Dex劑量不同將入組患者隨機(jī)分為低、中、高劑量組,每組各40例,Dex劑量分別為0.2 μg/(kg·h)、0.4 μg/(kg·h)及0.8 μg/(kg·h)。3組患者性別、年齡、體重、病情分級(jí)等資料比較,差異無(wú)統(tǒng)計(jì)學(xué)意義 (P>0.05)。
1.2方法
3組患者均給予靜吸復(fù)合麻醉。進(jìn)入手術(shù)室后常規(guī)開(kāi)放外周靜脈,建立有創(chuàng)動(dòng)脈壓。麻醉誘導(dǎo)方案:舒芬太尼0.3 μg/kg,維庫(kù)溴銨0.1 mg/kg,依托咪酯0.2 mg/kg,異丙酚1~3 mg/kg;氣管插管后調(diào)節(jié)呼吸機(jī)參數(shù),呼吸比1∶2,潮氣量8 mL/kg,通氣頻率12次/min,氧流量2 L/min;術(shù)中吸入七氟醚進(jìn)行麻醉維持并間斷靜脈推注維庫(kù)溴銨維持肌松,維持BIS值35~45。3組患者均在麻醉誘導(dǎo)后15 min,給予Dex負(fù)荷劑量1.0 μg/kg緩慢泵注,10 min內(nèi)完成;術(shù)中分別給予0.2 μg/(kg·h)、0.4 μg/(kg·h)及0.8 μg/(kg·h)右美托咪定微泵注入。術(shù)中如出現(xiàn)收縮壓低于90 mmHg及時(shí)靜脈推注多巴胺(2 mg/次),心率低于50次/min靜脈推注阿托品(0.5 mg/次)。
1.3觀察指標(biāo)
(1)躁動(dòng)評(píng)分:安靜合作為0分,被詢(xún)問(wèn)時(shí)主訴不適但不伴有行為反應(yīng)為1分,頻繁主訴不適為2分,有四肢亂動(dòng)等行為反應(yīng)為3分;記錄患者蘇醒過(guò)程中Ramsay鎮(zhèn)靜評(píng)分:煩躁為1分、安靜合作為2分、嗜睡但能聽(tīng)從指令3分、睡眠狀態(tài)但是可喚醒為4分、呼喚反應(yīng)遲鈍為5分、深睡喚之不醒為6分。(2)在蘇醒過(guò)程中,記錄患者的呼吸恢復(fù)時(shí)間、呼之睜眼時(shí)間、拔管時(shí)間。(3)蘇醒期生命體征, 在蘇醒過(guò)程中,記錄心率(heart rate, HR)變化,并計(jì)算心臟指數(shù)[cardiac index(CI),心率×每搏指數(shù)/1 000]、心率與收縮壓乘積(RPP)。(4)蘇醒期應(yīng)激反應(yīng)指標(biāo):在蘇醒過(guò)程中,采集患者的血清標(biāo)本,酶聯(lián)免疫吸附法檢測(cè)皮質(zhì)醇(cortisol, Cor)、腎上腺素(epinephrine, E)、去甲腎上腺素(norepinephrine, NE)含量。
1.4統(tǒng)計(jì)學(xué)方法
2結(jié)果
2.1躁動(dòng)評(píng)分和鎮(zhèn)靜評(píng)分
大劑量組和中劑量組患者的躁動(dòng)評(píng)分低于低劑量組、鎮(zhèn)靜評(píng)分高于低劑量組(P<0.05),且大劑量組的躁動(dòng)評(píng)分、鎮(zhèn)靜評(píng)分與中劑量組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);低劑量組和中劑量組的呼吸恢復(fù)時(shí)間、呼之睜眼時(shí)間、拔管時(shí)間短于高劑量組(P<0.05),中劑量組的呼吸恢復(fù)時(shí)間、呼之睜眼時(shí)間、拔管時(shí)間與低劑量組差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)表1。
±s)
(1)與低劑量組比較,P<0.05;(2)與中劑量組比較,P<0.05
2.2蘇醒期生命體征
麻醉蘇醒期,中劑量和高劑量組的HR、CI、RPP均低于低劑量組(P<0.05),且中劑量組HR、CI、RPP與低劑量組差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)表2。
表2不同劑量Dex組神經(jīng)外科手術(shù)
Tab.2 Vital signs index of recovery stage of
DexHR(次/min)CI(min·m2)?RPP(×103)低劑量組 94.41±10.284.11±0.5212.03±1.62中劑量組 85.25±9.31(1)3.08±0.41(1)9.78±1.04(1)大劑量組 84.89±9.97(1)3.02±0.44(1)9.65±0.94(1)F5.2345.4856.028P<0.05<0.05<0.05
(1)與低劑量組比較,P<0.05
2.3蘇醒期應(yīng)激反應(yīng)
中劑量組、大劑量組Cor、E、NE含量均明顯低于低劑量組,且中劑量組與高劑量組間比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)表3。
表3不同劑量Dex組神經(jīng)外科手術(shù)患者
Tab.3 Stress response index of recovery stage
DexCorENE低劑量組 294.41±34.22231.13±32.62282.29±35.14中劑量組 187.92±25.22(1)187.34±23.66(1)154.3±24.23(1)大劑量組 183.42±22.34(1)182.34±19.34(1)156.65±19.34(1)F7.1926.5858.592P<0.05<0.05<0.05
(1)與低劑量組比較,P<0.05
3討論
近年來(lái),Dex已經(jīng)成為了全身靜脈麻醉的常規(guī)用藥,能夠與常規(guī)麻醉藥物發(fā)揮協(xié)同效應(yīng),起到良好的中樞鎮(zhèn)靜作用,且不會(huì)產(chǎn)生明顯的呼吸抑制效應(yīng)[4]。目前,臨床上使用Dex的劑量為0.2~1.0 μg/(kg·h),關(guān)于劑量的選擇尚無(wú)統(tǒng)一認(rèn)識(shí)[5]。有研究認(rèn)為,選擇大劑量的Dex能夠取得更為確切的鎮(zhèn)靜效果,避免蘇醒期躁動(dòng)的發(fā)生[6];但也有研究認(rèn)為,過(guò)大劑量的Dex會(huì)延長(zhǎng)蘇醒時(shí)間,同時(shí)影響麻醉后認(rèn)知功能的恢復(fù)[7]。因此,選擇合適劑量的Dex用于全身麻醉是臨床學(xué)者研究的熱點(diǎn)問(wèn)題[8];理想藥物劑量應(yīng)當(dāng)能夠?qū)崿F(xiàn)理想的鎮(zhèn)靜效果、預(yù)防蘇醒期躁動(dòng)的發(fā)生,同時(shí)不會(huì)影響蘇醒過(guò)程、不延長(zhǎng)麻醉蘇醒時(shí)間[9]。
蘇醒情況主要包括蘇醒期躁動(dòng)程度以及蘇醒時(shí)間。本研究中,中劑量組和高劑量組患者的鎮(zhèn)靜評(píng)分較高、躁動(dòng)評(píng)分較低,且兩組間差異無(wú)統(tǒng)計(jì)學(xué)意義。國(guó)內(nèi)外學(xué)者也有類(lèi)似的文獻(xiàn)報(bào)道,提示中劑量和高劑量所取得的鎮(zhèn)靜效應(yīng)相當(dāng)且均優(yōu)于低劑量[10]。從蘇醒時(shí)間的結(jié)果分析可知低劑量組和中劑量組的呼吸恢復(fù)時(shí)間、呼之睜眼時(shí)間、拔管時(shí)間較短,且兩組間差異無(wú)統(tǒng)計(jì)學(xué)意義,提示低劑量和中劑量所取得的蘇醒時(shí)間相當(dāng)且均短于高劑量。綜合比較,在3種不同的劑量中,中劑量Dex具備了高劑量鎮(zhèn)靜效果好、躁動(dòng)程度弱的優(yōu)勢(shì),同時(shí)也具備了低劑量蘇醒時(shí)間短的優(yōu)勢(shì)。
在麻醉蘇醒期,理想的鎮(zhèn)靜效果能夠預(yù)防蘇醒期躁動(dòng)的發(fā)生,進(jìn)而避免蘇醒期生命體征的波動(dòng)。本文研究中,中劑量和高劑量組HR、CI和RPP均低于低劑量組。這就進(jìn)一步明確了中劑量Dex確切的鎮(zhèn)靜效果,穩(wěn)定生命體征的效應(yīng)與高劑量Dex一致。蘇醒期鎮(zhèn)靜效果不佳及躁動(dòng)反應(yīng)的出現(xiàn)會(huì)導(dǎo)致應(yīng)激反應(yīng)激活,表現(xiàn)為多種激素釋放入血。腎上腺髓質(zhì)和皮質(zhì)是參與應(yīng)激反應(yīng)重要的靶腺體,所合成的皮質(zhì)激素皮質(zhì)醇能夠增強(qiáng)機(jī)體對(duì)傷害性刺激的耐受能力[11],髓質(zhì)激素腎上腺素和去甲腎上腺素能夠收縮外周小血管、影響生命體征[12]。本研究結(jié)果表明,中劑量和高劑量組的血清Cor、Ne、E含量均低于低劑量組,且兩組間應(yīng)激激素含量差異無(wú)統(tǒng)計(jì)學(xué)意義。
綜上所述,中劑量Dex能夠減輕躁動(dòng)程度、穩(wěn)定生命體征、緩解應(yīng)激反應(yīng),同時(shí)又不會(huì)延長(zhǎng)蘇醒時(shí)間。本文研究的局限性在于缺乏對(duì)生命體征、應(yīng)激反應(yīng)的動(dòng)態(tài)觀察,有待于今后擴(kuò)大樣本展開(kāi)研究。
4參考文獻(xiàn)
[1] 鄭勇萍,郭偉,張宗澤.不同劑量的右美托咪定對(duì)全麻開(kāi)胸手術(shù)患者蘇醒期躁動(dòng)及炎性細(xì)胞因子的影響[J].武漢大學(xué)學(xué)報(bào):醫(yī)學(xué)版, 2013 (1):113-117.
[2] Naithani U, Meena MS, Gupta S, et al. Dose-dependent effect of intrathecal dexmedetomidine on isobaric ropivacaine in spinal anesthesia for abdominal hysterectomy: Effect on block characteristics and hemodynamics[J]. J Anaesthesiol Clin Pharmacol, 2015 (1):72-79.
[3] 陳君,佟小光.右美托咪啶聯(lián)合全身麻醉在頸動(dòng)脈內(nèi)膜切除術(shù)中的應(yīng)用[J].中國(guó)現(xiàn)代神經(jīng)疾病雜志, 2014(2):87-92.
[4] 譚文斐,姜艷華,馬虹,等.喉罩聯(lián)合右美托咪定在神經(jīng)介入手術(shù)中的應(yīng)用[J].中國(guó)現(xiàn)代醫(yī)學(xué)雜志, 2014(5):81-83.
[5] Bergese SD, Patrick Bender S, McSweeney TD, et al. A comparative study of dexmedetomidine with midazolam and midazolam alone for sedation during elective awake fiberoptic intubation[J]. J Clin Anesth, 2010(1):35-40.
[6] 林賽娟,姚歡琦,田國(guó)剛,等.右美托咪定與異丙酚復(fù)合麻醉對(duì)腦腫瘤切除術(shù)患者腦保護(hù)效應(yīng)的比較[J].中華麻醉學(xué)雜志, 2014(6):657-660.
[7] 張奕文,何忠承,石世堅(jiān).右美托咪定復(fù)合七氟烷全麻對(duì)老年患者術(shù)后早期認(rèn)知功能的影響[J].廣東醫(yī)學(xué), 2012(14):2172-2174.
[8] Inoue A, Tagawa M, Nishikawa M, et al. Emergency carotid artery stenting within 24 hours after intravenous thrombolysis for acute ischemic stroke: a case report[J]. No Shinkei Geka, 2013(7):609-617.
[9] 林萬(wàn)春,于天超,崔丹,等.右美托咪定復(fù)合芬太尼在腦室鉆孔引流術(shù)麻醉中的應(yīng)用[J].齊齊哈爾醫(yī)學(xué)院學(xué)報(bào), 2015(2):231-232.
[10]Chaitanya G, Arivazhagan A, Sinha S, et al. Hemodynamic effects of dexmedetomidine during intra-operative electrocorticography for epilepsy surgery[J]. J Neurosci Rural Pract, 2014(Suppl 1): S17-21.
[11]Inoue A, Tagawa M, Nishikawa M, et al. Emergency carotid artery stenting within 24 hours after intravenous thrombolysis for acute ischemic stroke: a case report[J]. No Shinkei Geka, 2013(7):609-617.
[12]Gul S, Hanci V, Bahadir B, et al. The effectiveness of dexmedetomidine in experimental spinal cord injury compared to methylprednisolone in rats[J]. J Clin Neurosci, 2010(4):490-494.
(2015-10-05收稿,2015-12-18修回)
中文編輯: 周凌; 英文編輯: 趙毅
Effect of Varied Dosages of Dexmedetomidine on Recovery Quality of General Anesthesia in Neurosurgery Patients
ZHANG Wenjuan1, FANG Kaiyun2
(1.GuizhouMedicalUniversity,Guiyang550025,Guizhou,China; 2.DepartmentofAnesthesia,AffiliatedPeople'sHospitalofGuizhouMedicalUniversity,Guiyang550001,Guizhou,China)
[Abstract]Objective: To investigate the effect of different dosages of dexmedetomidine (Dex) on recovery quality of general anesthesia in neurosurgery patients. Methods: A total of120 patients received neurosurgery and were divided into low dosage group, medium dosage group and the high-dosage group according to the amount of received dosages of Dex. Then comparing following indexes of three groups: sedation-agitation scale, sedation score, breathing recovery time, eye-opening time, extubation time, heart rate (HR),cardiac index(CI), rate pressure product(RPP); then testing stress response index during recovery process, including: cortisol (Cor), epinephrine (E) and norepinephrine (NE). Results: Agitation scores of high-dosage group and medium dosage group were lower than the low-dosage group, sedation scores were higher than that of low-dosage group(P<0.05), there were no statistical difference of agitation and sedation scores between high-dosage group and medium dosage group; breathe recovery time, eye-openning time, extubation time of low dosage group and medium dosage group were shorter than high-dosage group(P<0.05), there were no statistical difference of recovery time between low dosage group and medium dosage group(P>0.05). HR, CI, RPP, Cor, NE, E of high-dosage group and medium dosage group were lower than low dosage group(P<0.05), there were no statistical difference of vital signs and stress hormone between high-dosage group and medium dosage group(P>0.05). Conclusion: Wake effect of medium dosage Dex was the best, it could reduce the degree of agitation, stable vital signs, relieve stress, while not prolong recovery time.
[Key words]dexmedetomidine; neurosurgery; anesthesia, general; sedation; stress
[中圖分類(lèi)號(hào)]R614.2
[文獻(xiàn)標(biāo)識(shí)碼]A
[文章編號(hào)]1000-2707(2016)01-0099-04
*貴州醫(yī)科大學(xué)2013級(jí)在讀研究生
**通信作者 E-mail:fankaiyun@sina.com
網(wǎng)絡(luò)出版時(shí)間:2016-01-07網(wǎng)絡(luò)出版地址:http://www.cnki.net/kcms/detail/52.5012.R.20160107.2030.040.html